Expertise in
13
conditions

Stefano Volpetti

Udine, IT 
Expertise in
13
conditions
Udine, IT 

Overview

Stefano Volpetti practices practicing medicine in Udine, Italy.

Mr. Volpetti is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Adult Immune Thrombocytopenia, Bone Marrow Transplant, and Splenectomy.

He is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Udine, 33100, Italy
Other Locations
Trieste, Italy
Catania, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Enrollment Status: Completed
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: Romidepsin, CHOEP-21
Study Phase: Phase 1/Phase 2
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
A Phase II, Open Label, Multicenter Trial of Venetoclax (ABT-199/GDC-0199) as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal T-cell Lymphomas of T-follicular Helper Origin (TFH)
A Phase II, Open Label, Multicenter Trial of Venetoclax (ABT-199/GDC-0199) as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal T-cell Lymphomas of T-follicular Helper Origin (TFH)
Enrollment Status: Terminated
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Enrollment Status: Completed
Publish Date: March 22, 2022
Intervention Type: Drug
Study Drug: Brentuximab Vedotin
Study Phase: Phase 2
View 3 Less Clinical Trials

45 Total Publications

Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review.
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review.
Journal: Cancers
Published: March 07, 2024

Frequently Asked Questions about Stefano Volpetti

Is Stefano Volpetti a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Stefano Volpetti is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stefano Volpetti participate in research or clinical trials?

Yes. Stefano Volpetti has published 45 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Stefano Volpetti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Volpetti's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile